4//SEC Filing
Laliberte Kevin 4
Accession 0001209191-17-059802
CIK 0001685071other
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 5:14 PM ET
Size
6.4 KB
Accession
0001209191-17-059802
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Award
Employee Stock Option (Right to Buy)
2017-11-06+24,750→ 24,750 totalExercise: $3.73Exp: 2027-03-27→ Common Stock (24,750 underlying)
Footnotes (2)
- [F1]The Reporting Person was granted a stock option on March 28, 2017 (the "Date of Grant") providing for milestone vesting based on the Issuer's successful completion of two Phase IIIB/IV clinical trial protocols as determined and certified in writing by the Board of Directors (the "Board"). Such milestone was achieved on September 29, 2017 and certified by the Board on November 6, 2017. The exercise price of the option is the fair market value of the Issuer's Common Stock on the Date of Grant.
- [F2]The option shall vest over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on September 29, 2018, and (ii) the balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments beginning on October 29, 2018, subject to the Person's continuous service with the Issuer as of each such date. In addition, the option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.
Documents
Issuer
Dova Pharmaceuticals, Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001709417
Filing Metadata
- Form type
- 4
- Filed
- Nov 7, 7:00 PM ET
- Accepted
- Nov 8, 5:14 PM ET
- Size
- 6.4 KB